Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA803
1.1 Risankizumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have:
peripheral arthritis with 3 or more tender joints and 3 or more swollen joints
moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)
had 2 conventional DMARDs and at least 1 biological DMARD.
Risankizumab is recommended only if the company provides it according to the commercial arrangement.